These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 34398034)
1. Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy: A retrospective study. Liu Q; Zhao C; Jiang P; Liu D Medicine (Baltimore); 2021 Jul; 100(29):e26674. PubMed ID: 34398034 [TBL] [Abstract][Full Text] [Related]
2. Dynamic changes in PD-L1 expression and CD8 Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259 [TBL] [Abstract][Full Text] [Related]
3. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer. Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568 [TBL] [Abstract][Full Text] [Related]
4. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients. El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis. Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer. Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. Gao Y; Li S; Xu D; Chen S; Cai Y; Jiang W; Zhang X; Sun J; Wang K; Chang B; Wang F; Hong M Chin J Cancer; 2017 Jul; 36(1):61. PubMed ID: 28754154 [TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821 [TBL] [Abstract][Full Text] [Related]
9. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175 [TBL] [Abstract][Full Text] [Related]
10. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy. Wei Z; Zhan X; Fan L; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y; Li Q Int J Hyperthermia; 2018; 35(1):591-598. PubMed ID: 30307348 [TBL] [Abstract][Full Text] [Related]
11. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer. Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992 [TBL] [Abstract][Full Text] [Related]
12. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231 [TBL] [Abstract][Full Text] [Related]
13. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer. Chen YL; Huang WC; Lin FM; Hsieh HB; Hsieh CH; Hsieh RK; Chen KW; Yen MH; Lee J; Su S; Marfatia T; Chang SE; Sundar P; Patterson B; Watson D; Mei R; Javey M Cancer Immunol Immunother; 2019 Jul; 68(7):1087-1094. PubMed ID: 31089757 [TBL] [Abstract][Full Text] [Related]
14. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135 [TBL] [Abstract][Full Text] [Related]
15. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer. Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741 [TBL] [Abstract][Full Text] [Related]
16. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008 [TBL] [Abstract][Full Text] [Related]
18. Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8 Munari E; Marconi M; Querzoli G; Lunardi G; Bertoglio P; Ciompi F; Tosadori A; Eccher A; Tumino N; Quatrini L; Vacca P; Rossi G; Cavazza A; Martignoni G; Brunelli M; Netto GJ; Moretta L; Zamboni G; Bogina G Front Immunol; 2021; 12():680973. PubMed ID: 34122444 [TBL] [Abstract][Full Text] [Related]
19. The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer. Yang L; Zhang W; Sun J; Yang G; Cai S; Sun F; Xing L; Sun X Cancer Immunol Immunother; 2023 Jul; 72(7):2015-2027. PubMed ID: 36738309 [TBL] [Abstract][Full Text] [Related]
20. Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Fujimoto D; Uehara K; Sato Y; Sakanoue I; Ito M; Teraoka S; Nagata K; Nakagawa A; Kosaka Y; Otsuka K; Imai Y; Hamakawa H; Takahashi Y; Kokubo M; Tomii K Sci Rep; 2017 Sep; 7(1):11373. PubMed ID: 28900290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]